This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ piribedil hydrochloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Depression: Pirlindole mesylate is indicated for the treatment of depression, including major depressive disorder (MDD). It works by inhibiting the enzyme monoamine oxidase A (MAO-A), which increases the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain. By enhancing neurotransmitter activity, pirlindole mesylate helps alleviate depressive symptoms such as low mood, loss of interest or pleasure, fatigue, changes in appetite, and sleep disturbances.

  2. Monoamine Oxidase Inhibition: As a reversible inhibitor of MAO-A, pirlindole mesylate selectively and reversibly blocks the breakdown of monoamine neurotransmitters in the brain. This mechanism of action differs from that of traditional monoamine oxidase inhibitors (MAOIs), which irreversibly inhibit MAO enzymes and require dietary restrictions due to the risk of tyramine-induced hypertensive crisis.

  3. Symptom Improvement: Pirlindole mesylate treatment has been shown to lead to improvements in mood, energy levels, motivation, concentration, and overall functioning in individuals with depression. It may also help reduce feelings of anxiety and agitation associated with depressive disorders.

  4. Onset of Action: Pirlindole mesylate typically exhibits a relatively rapid onset of action compared to some other antidepressant medications. Some patients may experience symptom relief within a few weeks of starting treatment, although full therapeutic effects may take several weeks to manifest.

  5. Side Effects: Common side effects associated with pirlindole mesylate therapy may include dizziness, drowsiness, headache, nausea, dry mouth, constipation, blurred vision, and sexual dysfunction. Most side effects are mild to moderate in severity and tend to improve over time. However, individuals experiencing severe or persistent side effects should consult their healthcare provider.

  6. Cardiovascular Effects: Pirlindole mesylate has a favorable side effect profile in terms of cardiovascular safety compared to older MAOIs. It generally does not significantly affect blood pressure or heart rate and is less likely to cause orthostatic hypotension or hypertensive crises associated with dietary tyramine intake.

  7. Liver Function Monitoring: Patients taking pirlindole mesylate should undergo periodic monitoring of liver function tests, as rare cases of liver toxicity have been reported with its use. If signs of liver dysfunction such as jaundice, abdominal pain, or unexplained fatigue occur, medical attention should be sought promptly.

  8. Contraindications: Pirlindole mesylate is contraindicated in individuals with a history of hypersensitivity to the drug, severe liver impairment, pheochromocytoma, and concurrent use of other MAOIs or certain medications metabolized by MAO enzymes. It should not be used concomitantly with serotonergic agents due to the risk of serotonin syndrome.

  9. Drug Interactions: Pirlindole mesylate may interact with other medications, including antidepressants, sympathomimetic agents, antihypertensive drugs, and certain herbal supplements. Healthcare providers should review the patient's medication regimen carefully to avoid potential drug interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of piribedil hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Anaerobutyricum hallii Reduces
species Blautia wexlerae Reduces
species Christensenella minuta Reduces
species Enterococcus faecium Reduces
species Lactococcus cremoris Reduces

Bacteria Impacted by piribedil hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Dorea genus Decreases
0 1 Coprococcus genus Decreases
0 1 Bilophila genus Decreases
0 1 Ruminococcus genus Decreases
0 1 Anaerobutyricum genus Decreases
1 0 Akkermansia genus Decreases
0 1 Komagataeibacter genus Decreases
0 1 Eggerthella genus Decreases
0 1 Wansuia genus Decreases
0 1 Faecalitalea genus Decreases
0 1 Novisyntrophococcus genus Decreases
0 1 Lachnoanaerobaculum genus Decreases
0 1 Qiania genus Decreases
0 1 Olsenella genus Decreases
0 1 Christensenella genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Streptococcus genus Decreases
0 1 Lachnospira genus Decreases
0 1 Bacteroides genus Decreases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
1 0 Coprococcus comes species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Bilophila wadsworthia species Decreases
1 0 Ruminococcus bromii species Decreases
0 1 Anaerobutyricum hallii species Decreases
1 0 Akkermansia muciniphila species Decreases
0 1 Blautia sp. SC05B48 species Decreases
0 1 Komagataeibacter oboediens species Decreases
0 1 Dorea longicatena species Decreases
1 0 Eggerthella lenta species Decreases
0 1 Coprococcus catus species Decreases
0 1 Blautia obeum species Decreases
0 1 Blautia liquoris species Decreases
0 1 Lachnoanaerobaculum gingivalis species Decreases
0 1 Novisyntrophococcus fermenticellae species Decreases
0 1 Wansuia hejianensis species Decreases
0 1 Faecalitalea cylindroides species Decreases
0 1 Qiania dongpingensis species Decreases
0 1 Anaerostipes hadrus species Decreases
0 1 Lactococcus cremoris species Decreases
0 1 Ligilactobacillus ruminis species Decreases
0 1 [Ruminococcus] torques species Decreases
0 1 Eubacterium ventriosum species Decreases
0 1 Adlercreutzia equolifaciens species Decreases
0 1 Streptococcus suis species Decreases
0 1 Lachnoclostridium phocaeense species Decreases
0 1 Ruminococcus gauvreauii species Decreases
0 1 Clostridium cadaveris species Decreases
0 1 Christensenella minuta species Decreases
1 0 Mediterraneibacter gnavus species Decreases
0 1 Longicatena caecimuris species Decreases
0 1 Lacrimispora saccharolytica species Decreases
0 1 [Ruminococcus] lactaris species Decreases
0 1 Marvinbryantia formatexigens species Decreases
0 1 Solibaculum mannosilyticum species Decreases
0 1 Fannyhessea vaginae species Decreases
0 1 Mogibacterium diversum species Decreases
0 1 Coprococcus eutactus species Decreases
0 1 Butyrivibrio crossotus species Decreases
0 1 Clostridium sp. SY8519 species Decreases
0 1 Actinomyces oris species Decreases
0 1 Maliibacterium massiliense species Decreases
0 1 Faecalibacillus intestinalis species Decreases
0 1 Clostridium sp. M62/1 species Decreases
0 1 Parvimonas micra species Decreases
0 1 Bacillus paralicheniformis species Decreases
0 1 Blautia wexlerae species Decreases
0 1 Treponema denticola species Decreases
0 1 Adlercreutzia hattorii species Decreases
0 1 Catenibacterium mitsuokai species Decreases
0 1 Faecalibacterium duncaniae species Decreases
0 1 Eubacterium sp. MSJ-33 species Decreases
0 1 Subdoligranulum variabile species Decreases
0 1 Corynebacterium durum species Decreases
0 1 Massilistercora timonensis species Decreases
0 1 Coprococcus sp. ART55/1 species Decreases
0 1 Faecalibaculum rodentium species Decreases
0 1 Catenibacterium sp. co_0103 species Decreases
0 1 Enterococcus faecium species Decreases
0 1 Olsenella sp. oral taxon 807 species Decreases
0 1 Treponema peruense species Decreases
0 1 Eubacterium sp. c-25 species Decreases
0 1 Actinomyces naeslundii species Decreases
0 1 Enterococcus cecorum species Decreases
0 1 Intestinibaculum porci species Decreases
0 1 Faecalibacterium sp. I4-1-79 species Decreases
0 1 [Clostridium] hylemonae species Decreases
0 1 Faecalibacterium sp. I2-3-92 species Decreases
0 1 [Eubacterium] hominis species Decreases
0 1 Ruminococcus bovis species Decreases
0 1 Emergencia timonensis species Decreases
0 1 Faecalibacterium sp. HTF-F species Decreases
0 1 Roseburia hominis species Decreases
0 1 Butyricicoccus sp. GAM44 species Decreases
0 1 Pseudobutyrivibrio xylanivorans species Decreases
0 1 Faecalibacterium sp. IP-3-29 species Decreases
0 1 Ruminococcus albus species Decreases
0 1 Eubacterium limosum species Decreases
0 1 Romboutsia ilealis species Decreases
0 1 Wujia chipingensis species Decreases
0 1 Mageeibacillus indolicus species Decreases
0 1 Phascolarctobacterium succinatutens species Decreases
0 1 Eubacterium callanderi species Decreases
0 1 Phoenicibacter congonensis species Decreases
0 1 Monoglobus pectinilyticus species Decreases
0 1 Clostridioides difficile species Decreases
0 1 Vescimonas fastidiosa species Decreases
0 1 Eubacterium maltosivorans species Decreases
0 1 Vescimonas coprocola species Decreases
0 1 Ruminococcus champanellensis species Decreases
0 1 Faecalibacterium sp. I3-3-89 species Decreases
0 1 Faecalibacterium sp. IP-1-18 species Decreases
0 1 Turicibacter bilis species Decreases
0 1 Anaerotruncus colihominis species Decreases
0 1 Ruminococcus bicirculans (ex Wegman et al. 2014) species Decreases
0 1 Roseburia rectibacter species Decreases
0 1 Acutalibacter muris species Decreases
0 1 Butyrivibrio fibrisolvens species Decreases
0 1 Faecalibacterium sp. I4-3-84 species Decreases
0 1 Streptococcus mutans species Decreases
0 1 Blautia pseudococcoides species Decreases
0 1 Faecalibacterium sp. I3-3-33 species Decreases
0 1 Actinomyces sp. oral taxon 171 species Decreases
0 1 Actinomyces sp. oral taxon 169 species Decreases
0 1 Oscillibacter hominis species Decreases
0 1 Alistipes ihumii species Decreases
0 1 Roseburia intestinalis species Decreases
0 1 Romboutsia sp. 13368 species Decreases
1 0 Streptococcus parasanguinis species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
1 0 Bacteroides ovatus species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Bacteroides fragilis species Decreases

Impact of piribedil hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
ADHD 0.3 0.9 -2
Age-Related Macular Degeneration and Glaucoma 0.6 0.6
Allergic Rhinitis (Hay Fever) 0.9 0.4 1.25
Allergies 1.8 1 0.8
Allergy to milk products 0.9 0.3 2
Alopecia (Hair Loss) 0.5 0.1 4
Alzheimer's disease 1.8 1.6 0.13
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.3 0.6 1.17
Ankylosing spondylitis 0.7 0.4 0.75
Anorexia Nervosa 0.2 0.3 -0.5
Antiphospholipid syndrome (APS) 0.1 0.2 -1
Asthma 0.8 0.5 0.6
Atherosclerosis 0.5 0.3 0.67
Atrial fibrillation 1 0.2 4
Autism 2.6 1.9 0.37
Autoimmune Disease 0 0
Barrett esophagus cancer 0 0
benign prostatic hyperplasia 0 0
Biofilm 0.4 0.4
Bipolar Disorder 0.5 0.6 -0.2
Brain Trauma 0.2 0.2 0
Cancer (General) 0.1 -0.1
Carcinoma 1 0.6 0.67
Celiac Disease 0.2 1 -4
Cerebral Palsy 0.2 0.2 0
Chronic Fatigue Syndrome 1.3 3.7 -1.85
Chronic Kidney Disease 1.3 1.2 0.08
Chronic Lyme 0.1 0 0
Chronic Obstructive Pulmonary Disease (COPD) 0.4 0.4 0
Chronic Urticaria (Hives) 0 0.3 0
Coagulation / Micro clot triggering bacteria 0.1 0.2 -1
Cognitive Function 0.7 0.1 6
Colorectal Cancer 0.8 0.2 3
Constipation 0.2 0.2
Coronary artery disease 0.8 0.8 0
COVID-19 2.3 4.5 -0.96
Crohn's Disease 1.8 1.9 -0.06
Cushing's Syndrome (hypercortisolism) 0 0
cystic fibrosis 0 0
deep vein thrombosis 0.5 0.2 1.5
Denture Wearers Oral Shifts 0.3 0.3
Depression 2.3 2.7 -0.17
Dermatomyositis 0 0
Eczema 0.2 0.1 1
Endometriosis 0.9 0.5 0.8
Eosinophilic Esophagitis 0 0
Epilepsy 0.4 0.5 -0.25
erectile dysfunction 0 0
Fibromyalgia 0.6 0.7 -0.17
Functional constipation / chronic idiopathic constipation 0.8 0.8 0
gallstone disease (gsd) 0.9 0.2 3.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 1 0
Generalized anxiety disorder 0.8 0.5 0.6
Glioblastoma 0 0
Gout 0.4 0.5 -0.25
Graves' disease 0.2 0.8 -3
Gulf War Syndrome 0.3 0.5 -0.67
Halitosis 0 0 0
Hashimoto's thyroiditis 1.3 0.6 1.17
Heart Failure 1 0.6 0.67
hemorrhagic stroke 0.4 0.4
Hidradenitis Suppurativa 0.3 0.3
High Histamine/low DAO 0.2 -0.2
hypercholesterolemia (High Cholesterol) 0.4 -0.4
hyperglycemia 0.1 0.5 -4
Hyperlipidemia (High Blood Fats) 0.4 0.4
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 1.5 1.2 0.25
Hypothyroidism 0.2 0.4 -1
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 0.5 0.4 0.25
Inflammatory Bowel Disease 1.3 3 -1.31
Insomnia 1.1 0.8 0.38
Intelligence 0.3 0.3
Intracranial aneurysms 0.2 0.3 -0.5
Irritable Bowel Syndrome 1.4 1.1 0.27
ischemic stroke 0.2 0 0
Juvenile idiopathic arthritis 0.1 0.1
Liver Cirrhosis 1.6 1.7 -0.06
Long COVID 1.9 2.6 -0.37
Low bone mineral density 0.7 -0.7
Lung Cancer 0.2 1.2 -5
Mast Cell Issues / mastitis 0 0.5 0
ME/CFS with IBS 0 2.3 0
ME/CFS without IBS 0.8 1.3 -0.63
membranous nephropathy 0 0
Menopause 0.3 0.3 0
Metabolic Syndrome 2.5 2.4 0.04
Mood Disorders 2.5 1.8 0.39
multiple chemical sensitivity [MCS] 0.2 0.2
Multiple Sclerosis 1.9 1.5 0.27
Multiple system atrophy (MSA) 0.7 0.2 2.5
myasthenia gravis 0 0
neuropathic pain 0.1 0.3 -2
Neuropathy (all types) 0.4 0.4
neuropsychiatric disorders (PANDAS, PANS) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1 1.4 -0.4
NonCeliac Gluten Sensitivity 0.4 0 0
Obesity 3.4 2.7 0.26
obsessive-compulsive disorder 1.3 1.5 -0.15
Osteoarthritis 0.7 0.5 0.4
Osteoporosis 0.3 0.8 -1.67
pancreatic cancer 0 0 0
Parkinson's Disease 3 2 0.5
Polycystic ovary syndrome 1.3 1 0.3
Postural orthostatic tachycardia syndrome 0.3 -0.3
primary biliary cholangitis 0.5 0 0
Primary sclerosing cholangitis 0.3 1.3 -3.33
Psoriasis 1 0.6 0.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.8 0.8 2.5
Rosacea 0.4 0.4
Schizophrenia 1.7 0.7 1.43
scoliosis 0.5 0.4 0.25
sensorineural hearing loss 0.5 0.5
Sjögren syndrome 0 0.4 0
Sleep Apnea 0.9 0.4 1.25
Slow gastric motility / Gastroparesis 0.2 0.2
Small Intestinal Bacterial Overgrowth (SIBO) 0.5 0.5
Stress / posttraumatic stress disorder 0.7 0.9 -0.29
Systemic Lupus Erythematosus 0.9 0.4 1.25
Tic Disorder 0.2 0.7 -2.5
Tourette syndrome 0.6 0 0
Type 1 Diabetes 1.3 0.6 1.17
Type 2 Diabetes 2 1.4 0.43
Ulcerative colitis 0.9 1.8 -1
Unhealthy Ageing 1.6 0.5 2.2
Vitiligo 0.3 0.8 -1.67

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]